A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Active, not recruiting · Phase 1 · NCT05259709
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $765
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- 89Zr˗DFO˗REGN5054 (drug), cemiplimab (drug)
- Dates
- Started 2023-02-07; completion 2027-04-29
- Results posted
- Not yet
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer. The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the…
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $765 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $765
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.